IGNE IGENE Biotechnology Inc. featured news, full reports, and detailed charts
IGENE Biotechnology Inc. (IGNE/IGNE.PK) Wrap Up:
IGENE Biotechnology, Inc. engages in the development, production, and marketing of value-added specialty biochemical products in the United States and internationally. It primarily focuses on the research development of fermentation technology, nutrition, and health products and applications. The company offers AstaXin, a natural source of astaxanthin, which is a pigment that imparts the characteristic red color to the flesh of salmon, trout, prawns, and various other types of fish and shellfish. It also formulated natural astaxanthin as a super-antioxidant for the dietary supplement market. The company, formerly known as IGI Biotechnology, Inc., was founded in 1981 and is based in Columbia,...IGENE Biotechnology Inc. (IGNE:OTC)
|
Market Cap
28.1M
|
Total Revenue
6.0M
|
|
|
EBITDA
1.5M
|
DILUTED EPS TTM
0.00
|
|
|
P/E
--
|
P/S
4.6x
|
|
|
Return On Asset
-15.96
|
Return On Equity
22.41
|
|
| K = Thousands M = Millions B = Billions | ||
IGNE Top Compensated Officers
Executives, Board Directors
Key developments for IGENE Biotechnology Inc. (IGNE)
On 04/01/2009, IGENE Biotechnology Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
IGENE Biotechnology Inc. filed its 10-K on April 01, 2009 for the period ending December 31, 2008. In this report its auditor, McElravy, Kinchen & Associates PC, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
IGENE Biotechnology Inc. announced that it has entered into an agreement with Archer-Daniels-Midland Company pursuant to which the company and ADM formed a joint venture to manufacture and sell astaxanthin and derivative products throughout the world. Each of the company and ADM has a 50% ownership interest in the joint venture and has equal representation on the Board of Managers of the joint venture.
IGNE Competitors
| Company | Last | Change | |
| No competitor information is available for IGNE. | |||
| Market data is delayed at least 20 minutes. | |||
Industry Analysis
| Valuation | IGNE | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 4.6x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 4.4x |
|
|
IGNE |
||
IGNE transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||